JATT II Acquisition Corp. entered into a Business Combination Agreement on June 29, 2026, to merge with Talawar Tx Inc. via a merger with Talawar Merger Sub. Under the terms, JATT ordinary shares will convert into Talawar common stock following a stock split. The transaction includes a $225 million PIPE financing, where investors will purchase 22.5 million shares at $10.00 per share, implying a $120 million pre-PIPE equity valuation. The combined company intends to list on the Nasdaq Capital Market. JATT shareholders will have redemption rights for a pro rata portion of the trust account funds. Talawar Tx Inc. is a biotechnology company focused on clinical development.